Pneumologia - Curriculum Girbino - G. Martino
Pneumologia - Curriculum Girbino - G. Martino
Pneumologia - Curriculum Girbino - G. Martino
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Autori<br />
CAZZOLA M, MATERA MG, SANTANGELO G, ASSOGNA G, D'AMATO G, ROSSI F, GIRBINO G.<br />
Abstract<br />
IN EIGHT ASTHMATIC SUBJECTS A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WAS<br />
PERFORMED TO INVESTIGATE THE EFFECT OF INHALED KETANSERIN, A 5-HT2 RECEPTOR BLOCKING<br />
AGENT, IN A DOSE OF 10 MG GIVEN 30 MIN BEFORE TEST, ON ADENOSINE-INDUCED BRONCHOSPASM.<br />
THE PROTECTIVE EFFECT OF KETANSERIN WAS SIGNIFICANT IN ALL PATIENTS, EVEN THOUGH IT<br />
ALTERED BASAL BRONCHOMOTOR TONE IN ONLY TWO SUBJECTS. ON THE CONTRARY, KETANSERIN<br />
DID NOT INHIBIT HISTAMINE-INDUCED BRONCHOCONSTRICTION IN FOUR OF THESE EIGHT<br />
ASTHMATICS, EVEN THOUGH IT MODIFIED SENSITIVITY AND REACTIVITY IN ONE OF THEM. THE<br />
RESULTS SUGGEST THAT KETANSERIN INFLUENCE ON ADENOSINE BRONCHIAL REACTIVITY AND<br />
SENSITIVITY WAS NOT DUE TO THE BRONCHODILATOR EFFECT OF KETANSERIN ITSELF OR TO ITS<br />
ANTIHISTAMINIC ACTIVITY. WE HAVE NO CERTAIN EXPLANATION FOR THE INHIBITION OF ADENOSINE-<br />
INDUCED BRONCHOCONSTRICTION ELICITED BY KETANSERIN. IT IS POSSIBLE THAT 5-HT MAY PLAY,<br />
AT LEAST IN PART, A ROLE AS MEDIATOR OF ADENOSINE-INDUCED BRONCHOCONSTRICTION.<br />
Anno pubblicazione e riferimenti<br />
IMMUNOPHARMACOLOGY. 1992 JAN-FEB;23(1):21-8.<br />
ANNO: 1992 - ISBN:<br />
Titolo<br />
BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA: TRATTAMENTO AMBULATORIALE<br />
Autori<br />
G. GIRBINO M. CAZZOLA<br />
Abstract<br />
Anno pubblicazione e riferimenti<br />
ESI STAMPA MEDICA, 1999 ISBN 88-85675-07-7<br />
ANNO: 1992 - ISBN:<br />
Titolo<br />
INFLUENCE OF SULBACTAM PLUS AMPICILLIN ON THEOPHYLLINE CLEARANCE.<br />
Autori<br />
CAZZOLA M, SANTANGELO G, GUIDETTI E, MATTINA R, CAPUTI M, GIRBINO G.<br />
Abstract<br />
THE EFFECT OF SULBACTAM/AMPICILLIN (500 MG/1000 MG) EVERY 12 HOURS TAKEN FOR SEVEN DAYS<br />
ON THE STEADY-STATE PHARMACOKINETICS OF THEOPHYLLINE WAS STUDIED AMONG 12 PATIENTS<br />
SUFFERING FROM CHRONIC OBSTRUCTIVE PULMONARY DISEASE. THEOPHYLLINE CONCENTRATIONS<br />
WERE MEASURED SERIALLY FOR 12 H BY THE METHOD OF POLARIZED IMMUNOFLUORESCENCE<br />
(ABBOTT TDX SYSTEM). NO INFLUENCE OF SULBACTAM/AMPICILLIN WAS DETECTABLE ON THE<br />
THEOPHYLLINE HALF-LIFE, CLEARANCE OR VOLUME OF DISTRIBUTION. IT WAS CONCLUDED THAT<br />
BOTH DRUGS COULD BE ADMINISTERED CONCOMITANTLY WITHOUT ANY DOSAGE ADJUSTMENT OF<br />
THEOPHYLLINE.<br />
Anno pubblicazione e riferimenti<br />
INT J CLIN PHARMACOL RES. 1991;11(1):11-5.<br />
ANNO: 1991 - ISBN:<br />
Titolo<br />
PNEUMOCONIOSI ED ALTRE MALATTIE PROFESSIONALI DEL POLMONE<br />
Autori<br />
G. GIRBINO<br />
Abstract<br />
Anno pubblicazione e riferimenti<br />
POLMONE IN L. CARRATU’ , E. CATENA C. GRASSI MANUALE DI MALATTIE DELL’APPARATO<br />
RESPIRATORIE MASSON EDITRICE MILANO 221-238 ISBN 88-214-2085-X<br />
ANNO: 1991 - ISBN:<br />
Titolo<br />
A NEW ANTI-INFLAMMATORY--ANALGESIC--ANTIPYRETIC FOR THE TREATMENT OF ACUTE DISEASE OF<br />
THE BRONCHI<br />
Autori<br />
GIRBINO G, OLIANI C, LAURIELLO G, CONDOLUCI M.<br />
Abstract<br />
SIXTY ADULT PATIENTS, 31 MEN AND 29 WOMEN, AGED 44 TO 60, AND AFFECTED BY ACUTE<br />
BRONCHITIS OF PROBABLE BACTERIAL AETIOLOGY WERE RANDOMLY DIVIDED INTO 3 GROUPS OF 20<br />
AND TREATED RESPECTIVELY WITH: 1) MORNIFLUMATE (ONE 700 MG TABLET TWICE A DAY) +<br />
AMOXICILLIN (ONE 1 G TABLET TWICE A DAY); 2) FEPRAZONE (ONE 200 MG TABLET TWICE A DAY) +<br />
AMOXICILLIN (ONE 1 G TABLET TWICE A DAY); 3) AMOXICILLIN (ONE 1 G TABLET TWICE A DAY). MEAN<br />
THERAPY DURATION WAS 9 DAYS. THE ACTION OF THE DRUGS UNDER STUDY WAS ASSESSED BY<br />
OBJECTIVE CHEST EXAMINATION AND BY EVALUATING THE MODIFICATIONS OF COUGH INTENSITY<br />
AND FREQUENCY, CHEST PAIN EXPECTORATING DIFFICULTY, AMOUNT OF EXPECTORATION, BODY<br />
TEMPERATURE. THE OVERALL ASSESSMENTS WERE COMPLETED BY SIDE-EFFECT RECORDING AND<br />
BY LABORATORY EXAMINATIONS CARRIED OUT AT THE BEGINNING AND END OF THE STUDY. CHECKS<br />
WERE MADE REGULARLY ON ADMISSION, AND IN THE 3RD, 5TH, 7TH AND LAST DAY OF THERAPY. THE<br />
ABOVE MENTIONED PARAMETERS SHOWED A QUICKER REGRESSION OF BRONCHIAL INFLAMMATION<br />
IN THE SUBJECTS TREATED ALSO WITH THE ANTIINFLAMMATORY DRUG COMPARED TO THOSE<br />
TREATED ONLY WITH THE ANTIBIOTIC. FURTHERMORE, IN THE SUBJECTS TREATED WITH<br />
MORNIFLUMATE SUCH IMPROVEMENT WAS MORE RAPIDLY ACHIEVED COMPARED TO THOSE WHO<br />
RECEIVED FEPRAZONE. THE ANALGESIC AND ANTIPYRETIC EFFECTS OF MORNIFLUMATE WERE ALSO<br />
REMARKABLE. ALL TESTED DRUGS WERE WELL TOLERATED.